Drugs / Tumor infiltrating lymphocytes adoptive cell therapy (TIL-ACT) infusion
Tumor infiltrating lymphocytes adoptive cell therapy (TIL-ACT) infusion
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT06630611 Background | Jan 2025 → Sep 2029 expected | cervical cancer, melanoma, non-small cell lung carcinoma | Vall d'Hebron Institute of Oncology | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Tumor infiltrating lymphocytes adoptive cell therapy (TIL-ACT) infusion | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06630611 ↗ |
| Modality | Cell therapy | “TIL-based ACT (Adoptive cell therapy using tumor-infiltrating lymphocytes product)” NCT06630611 ↗ |
| Route | Intravenous | “Autologous TIL infusion will be administered intravenously.” NCT06630611 ↗ |